Literature DB >> 28597167

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.

Oussama Abla1, Raul C Ribeiro2, Anna Maria Testi3, Pau Montesinos4, Ursula Creutzig5, Lillian Sung6, Giancarlo Di Giuseppe6, Derek Stephens6, James H Feusner7, Bayard L Powell8, Henrik Hasle9, Gertjan J L Kaspers10, Luciano Dalla-Pozza11, Alvaro Lassaletta12, Martin S Tallman13, Franco Locatelli14,15, Dirk Reinhardt16, Francesco Lo-Coco17, Johann Hitzler6, Miguel A Sanz18,19.   

Abstract

Clinical trials on childhood acute promyelocytic leukemia (APL) report early death (ED) rates of 3-8%, but predictors of thrombohemorrhagic (TH)-ED are not well understood. In a retrospective study, we aimed to determine the incidence and predictors of TH-ED in childhood APL. Data were analyzed from children and adolescents with t(15;17)-positive APL (n = 683) who started treatment with all-trans retinoic acid (ATRA) and chemotherapy in different international studies. Demographic data; initial white blood cell (WBC), peripheral blood (PB) blast, and platelet counts; hemoglobin value; coagulation parameters; morphologic variant (M3 or M3v); and induction details were analyzed. Early death was defined as death occurring within 30 days of presentation. The incidence of ED was 4.7% (32 of 683 patients). Predictors of TH-ED were identified by univariable and multivariable Cox proportional hazard regression analyses (n = 25). In univariable analysis, high WBC (>10 × 109/L) (P < 0.001) and high PB blast (>30 × 109/L) (P < 0.001), M3v (P < 0.01), and black ethnicity (P < 0.001) were independent predictors of TH-ED. In multivariable analysis, high WBC count (P < 0.01) and obesity (i.e., body mass index ≥95th percentile for age) (P = 0.03) were predictors of TH-ED. Initial high WBC counts and obesity are likely predictors of TH-ED in childhood APL. The efficacy of novel drugs for APL-associated coagulopathy or of frontline arsenic trioxide and ATRA combination regimens in reducing ED rates in childhood APL remains to be established.

Entities:  

Keywords:  APL; Children; Early death; Predictors

Mesh:

Substances:

Year:  2017        PMID: 28597167     DOI: 10.1007/s00277-017-3042-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631.

Authors:  Madhvi Rajpurkar; Todd A Alonzo; Yi-Cheng Wang; Robert B Gerbing; Alan S Gamis; James H Feusner; John Gregory; Matthew A Kutny
Journal:  J Pediatr Hematol Oncol       Date:  2019-01       Impact factor: 1.289

2.  Predictive values of plasma TNFα and IL-8 for intracranial hemorrhage in patients with acute promyelocytic leukemia.

Authors:  Fangyi Dong; Li Chen; Chaoxian Zhao; Xiaoyang Li; Yun Tan; Huan Song; Wen Jin; Hongming Zhu; Yunxiang Zhang; Kai Xue; Junmin Li; Kankan Wang
Journal:  Front Med       Date:  2022-09-12       Impact factor: 9.927

3.  Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial.

Authors:  Senlin Luo; Jidong Tian; Xiao Sun; Feifeng Wu; Ying Liu; Wuqing Wan; Zhou She; Chuan Wen
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-05       Impact factor: 2.650

4.  An Outcome Analysis of Childhood Acute Promyelocytic Leukemia Treated with Atra and Arsenic Trioxide, and Limited Dose Anthracycline.

Authors:  Naeem Jabbar; Naema Khayyam; Uzma Arshad; Sidra Maqsood; Syed Ahmer Hamid; Neelum Mansoor
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-30       Impact factor: 0.915

5.  Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study.

Authors:  Zhi-Xiao Zhang; Ai-Dong Lu; Jun Wu; Ying-Xi Zuo; Yue-Ping Jia; Le-Ping Zhang; Jiong Qin
Journal:  J Cancer Res Clin Oncol       Date:  2020-10-02       Impact factor: 4.553

6.  Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.

Authors:  Hitoshi Minamiguchi; Hiroyuki Fujita; Yoshiko Atsuta; Norio Asou; Toru Sakura; Yasunori Ueda; Masashi Sawa; Nobuaki Dobashi; Yasuhiro Taniguchi; Rikio Suzuki; Yoshihito Uchino; Akihiro Tomita; Shigehisa Tamaki; Maki Hagihara; Katsumichi Fujimaki; Masamitsu Yanada; Yoshinobu Maeda; Masako Iwanaga; Noriko Usui; Yukio Kobayashi; Shigeki Ohtake; Hitoshi Kiyoi; Itaru Matsumura; Yasushi Miyazaki; Tomoki Naoe; Akihiro Takeshita
Journal:  Ann Hematol       Date:  2020-09-02       Impact factor: 3.673

7.  Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey.

Authors:  Tekin Aksu; Ali Fettah; İkbal Ok Bozkaya; Mehmet Baştemur; Abdurrahman Kara; Vildan Koşan Çulha; Namık Yaşar Özbek; Neşe Yaralı
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-07-01       Impact factor: 2.576

8.  Treatment Outcome and the Genetic Characteristics of Acute Promyelocytic Leukemia in Children in Poland From 2005 to 2018.

Authors:  Małgorzata Czogała; Katarzyna Pawińska-Wa Sikowska; Teofila Ksia Żek; Barbara Sikorska-Fic; Michał Matysiak; Anna Rodziewicz-Konarska; Alicja Chybicka; Jolanta Skalska-Sadowska; Jacek Wachowiak; Katarzyna Muszyńska-Rosłan; Maryna Krawczuk-Rybak; Dominik Grabowski; Jerzy Kowalczyk; Karolina Zielezińska; Tomasz Urasiński; Renata Tomaszewska; Tomasz Szczepański; Irena Karpińska-Derda; Mariola Woszczyk; Joanna Pohorecka; Grażyna Karolczyk; Wojciech Młynarski; Katarzyna Mycko; Wanda Badowska; Szymon Skoczeń; Walentyna Balwierz
Journal:  Front Pediatr       Date:  2020-03-20       Impact factor: 3.418

9.  Absolute Circulating Leukemic Cells as a Risk Factor for Early Bleeding Events in Patients with Non-High-Risk Acute Promyelocytic Leukemia.

Authors:  Yanru Pei; Mingyue Shi; Juanjuan Song; Xiaona Niu; Shengjie Wei; Liurui Dou; Mengyu Xiao; Dan Li; Fangfang Xu; Yanliang Bai; Kai Sun
Journal:  Cancer Manag Res       Date:  2021-05-21       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.